Latest immuno-oncology monotherapy data continue to cast doubt on combo strategies

New data for next generation immuno-oncology agents add to the debate of whether and how agents that show no efficacy as monotherapies in Phase I trials should be advanced to later stage combination trials. Merck & Co. Inc. (NYSE:MRK) and Eli Lilly and Co. (NYSE:LLY) each presented data at the European Society for Medical Oncology meeting in Munich showing

Read the full 592 word article

User Sign In